BioSpace News Archive

Evolent Health, Inc. (NYSE: EVH) today announced it will release its third quarter 2022 operating results on Wednesday, November 2, 2022 after market close, with a conference call to follow at 5:00 p.m. Eastern Time.

Biomerica, Inc. announced that under a General Merchandise Supplier Agreement with Walmart, the Company’s Aware® Breast Self Exam device will now be sold in over 2400 Walmart’s retail stores.

Maven Clinic, the world’s largest virtual clinic for women’s and family health, announced an agreement with Indira IVF to deliver high-quality fertility care to Maven members in India.

Indica Labs and Hamamatsu Photonics K.K. announced an agreement to maintain long-term interoperability between Indica Lab’s HALO AP® software platform and Hamamatsu’s NanoZoomer family of high-speed, high-resolution scanners.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R) announced today that it has finalized an amended protocol to the U.S. Food & Drug Administration (“FDA”) for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.

MY01 Inc. today announced that interim data from an ongoing, prospective multi-center study was presented at the Orthopaedic Trauma Association (OTA) Annual Meeting in Tampa, Florida.

Todos Medical, an in-vitro diagnostics company that develops reliable early-detection blood tests and related solutions for cancer, neurodegenerative disorders, and coronaviruses, announced the advancement of its Tollovir™ clinical trials for hospitalized COVID-19 patients.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced publication in the Cell Press journal Med of data detailing work relating to the discovery and preclinical profiling of STI-9167 neutralizing antibody activity against a broad collection of SARS-CoV-2 variants, including select Omicron subvariants.

Passage Bio, Inc. announced it has granted inducement awards to its newly appointed chief executive officer, William Chou, M.D.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today announced plans to restructure the Company to focus on the advancement of its platform in gene editing. Implementation of this strategy, which follows a strategic internal review by the Company’s board of directors and management team.